Seattle Genetics inks another antibody deal; Novartis expands ops in Bay Area; Cytokinetics raises $20M;

 @FierceBiotech: Regulators hand Eli Lilly another new drug rejection. Item | Follow @FierceBiotech

 @JohnCFierce: Domain Associates, GBS Venture Partners and BioPacificVentures hand CoDa Therapeutics a $19M Series B. Story | Follow @JohnCFierce

Demonstrating once again just how hot its antibody platform has become, Seattle Genetics announced this morning that it has struck a second pact with Genmab. The Danish biotech will use Seattle Genetics' ADC technology with HuMax-CD74, an antibody in pre-clinical development to target CD74, which is expressed on a range of hematological malignancies and solid tumors. Seattle Genetics received an undisclosed upfront payment and has the right to exercise a co-development and co-commercialization option for any resulting ADC products at the end of Phase I clinical development. Release

> Xconomy's Luke Timmerman recently toured Novartis's expanding operations in the Bay Area, where about 850 workers now labor. Story

> South San Francisco-based Cytokinetics has raised $20 million through the sale of 5.3 million shares. Release

> IBM's competitors are circling AstraZeneca after hearing that the big pharma company is cutting short its IT outsourcing contract with Big Blue. Story

> Amicus Therapeutics announced that John F. Crowley will transition from chairman and CEO to Executive Chairman in order to devote more time to interests related to public policy, civic service, and philanthropic endeavors. Amicus release

> Canada's PharmaGap says that initial results from preclinical testing provide evidence that a peptide formulation of PharmaGap's lead cancer drug GAP-107B8 administered via the intraperitoneal route can reduce tumour burden (19%) and significantly suppress ascites formation (73%) relative to controls. PharmaGap release

Pharma News

@FiercePharma: Warner Chilcott plots 500 job cuts in European revamp. Item | Follow @FiercePharma

> New Novartis drugs deliver Q1 sales growth. Article

> U.S. drug spending grows at anemic 2.3% in 2010. Report

Biotech Research News

> Stem cells from schizophrenics show how neurons make fewer connections. Story

> Parents surveyed would want gene tests for kids. News

> Science of addiction could offer alternatives to punishment of addict. Item 

> South African center to focus on regional drug-development needs. Report 

> Australia sees a gap in cancers represented in clinical trials. Story

> 'Accelerated evolution' gene could help predict preterm births. Article

Manufacturing News

> FDA achievements overlooked by critics. Story 

> Manufacturing cost gap closing among U.S., India, China. Article 

> Report: Pharma manufacturing "best bet" for college grads. News 

> FDA takes another look at cancer drug shortage. Story 

> Risk-based manufacturing gains steam at PDA. Report 

> Stirling cranks up Canada plant with tablet job. Item

And Finally... A new Mayo Clinic case study suggests that Botox could help patients suffering from low cerebrospinal fluid headaches. Release